FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004467890> ?p ?o ?g. }

• W2004467890 endingPage "2038" @default.
• W2004467890 startingPage "2031" @default.
• W2004467890 abstract "Background and Purpose Inflammation may play a role in delayed chronic vasospasm after aneurysmal subarachnoid hemorrhage. We investigated the role of intercellular adhesion molecule-1 (ICAM-1) and macrophage/granulocyte infiltration in the rat femoral artery model of vasospasm using systemic administration of a murine anti–ICAM-1 monoclonal antibody (MAb). Methods The femoral arteries (n=72) in Sprague-Dawley rats (n=36) were enclosed in latex pouches bilaterally. Autologous blood was injected into the pouch on one side, and saline was injected on the contralateral side. Chronic vessel narrowing was evaluated with the use of 29 rats, which were randomized into one of three groups for intraperitoneal injections: (1) anti–ICAM-1 MAb (2 mg/kg per dose, n=10), (2) isotype-matched MAb (2 mg/kg per dose, n=9), or (3) saline (n=10), given at 3 hours and 3, 6, and 9 days after blood exposure. These rats were killed 12 days after blood exposure, and femoral artery lumen cross-sectional areas were determined by computerized image analysis. Saturation of ICAM-1 binding sites with this dosing schedule was evaluated by fluorescence-activated cell sorter (FACS) analysis of splenocytes. Immunohistochemical studies with objective cell counts were performed to evaluate macrophage/granulocyte infiltration at 24 hours in 7 rats, comparing anti–ICAM-1 MAb treatment (n=4) with isotype-matched control MAb (n=3). Results Animals treated with anti–ICAM-1 MAb showed a significant inhibition of arterial narrowing at 12 days ( P =.0081), with lumen patency of 96.5±5.3% (mean±SEM), compared with 77.3±5.6% for isotype-matched MAb and 72.2±5.3% for saline-treated controls. FACS analysis of splenocytes from animals treated with anti–ICAM-1 MAb confirmed saturation of ICAM-1 binding sites. Vessels treated with anti–ICAM-1 MAb showed a significant decrease in inflammatory cell infiltrates, with objective macrophage/granulocyte counts of 31.3±26.6 (mean±SEM) per high-powered field, compared with 171.4±30.7 for isotype-matched control MAb ( P =.0027). Conclusions Anti–ICAM-1 MAb administered systemically starting 3 hours after blood exposure results in significant inhibition of chronic vasospasm in the rat femoral artery model and is correlated with a reduction in the number of infiltrating macrophages and granulocytes in the periadventitial region of blood-exposed arteries. We conclude that inflammatory changes associated with ICAM-1–mediated macrophage and granulocyte migration play an important role in the development of posthemorrhagic chronic vasospasm in this model." @default.
• W2004467890 created "2016-06-24" @default.
• W2004467890 creator A5011121905 @default.
• W2004467890 creator A5028066398 @default.
• W2004467890 creator A5041836945 @default.
• W2004467890 creator A5066707073 @default.
• W2004467890 creator A5084929123 @default.
• W2004467890 creator A5090582198 @default.
• W2004467890 date "1997-10-01" @default.
• W2004467890 modified "2023-10-14" @default.
• W2004467890 title "Inhibition of Experimental Vasospasm With Anti–Intercellular Adhesion Molecule-1 Monoclonal Antibody in Rats" @default.
• W2004467890 cites W1963972271 @default.
• W2004467890 cites W1965002463 @default.
• W2004467890 cites W1966286149 @default.
• W2004467890 cites W1967016288 @default.
• W2004467890 cites W1970025209 @default.
• W2004467890 cites W1971153516 @default.
• W2004467890 cites W1993014703 @default.
• W2004467890 cites W1995948010 @default.
• W2004467890 cites W2000303682 @default.
• W2004467890 cites W2000711829 @default.
• W2004467890 cites W2007027096 @default.
• W2004467890 cites W2007227258 @default.
• W2004467890 cites W2009766925 @default.
• W2004467890 cites W2015384236 @default.
• W2004467890 cites W2017347652 @default.
• W2004467890 cites W2027892619 @default.
• W2004467890 cites W2029896101 @default.
• W2004467890 cites W2030843837 @default.
• W2004467890 cites W2056244950 @default.
• W2004467890 cites W2062830078 @default.
• W2004467890 cites W2089686933 @default.
• W2004467890 cites W2092861594 @default.
• W2004467890 cites W2099675490 @default.
• W2004467890 cites W2104287195 @default.
• W2004467890 cites W2115048327 @default.
• W2004467890 cites W2119416030 @default.
• W2004467890 cites W2119810703 @default.
• W2004467890 cites W2126534770 @default.
• W2004467890 cites W2156076525 @default.
• W2004467890 cites W2163361020 @default.
• W2004467890 cites W2322367441 @default.
• W2004467890 cites W2461821931 @default.
• W2004467890 cites W4246836803 @default.
• W2004467890 cites W4247203928 @default.
• W2004467890 cites W4251350091 @default.
• W2004467890 cites W87100630 @default.
• W2004467890 doi "https://doi.org/10.1161/01.str.28.10.2031" @default.
• W2004467890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9341715" @default.
• W2004467890 hasPublicationYear "1997" @default.
• W2004467890 type Work @default.
• W2004467890 sameAs 2004467890 @default.
• W2004467890 citedByCount "89" @default.
• W2004467890 countsByYear W20044678902012 @default.
• W2004467890 countsByYear W20044678902013 @default.
• W2004467890 countsByYear W20044678902014 @default.
• W2004467890 countsByYear W20044678902015 @default.
• W2004467890 countsByYear W20044678902016 @default.
• W2004467890 countsByYear W20044678902017 @default.
• W2004467890 countsByYear W20044678902018 @default.
• W2004467890 countsByYear W20044678902021 @default.
• W2004467890 countsByYear W20044678902022 @default.
• W2004467890 countsByYear W20044678902023 @default.
• W2004467890 crossrefType "journal-article" @default.
• W2004467890 hasAuthorship W2004467890A5011121905 @default.
• W2004467890 hasAuthorship W2004467890A5028066398 @default.
• W2004467890 hasAuthorship W2004467890A5041836945 @default.
• W2004467890 hasAuthorship W2004467890A5066707073 @default.
• W2004467890 hasAuthorship W2004467890A5084929123 @default.
• W2004467890 hasAuthorship W2004467890A5090582198 @default.
• W2004467890 hasConcept C126322002 @default.
• W2004467890 hasConcept C142724271 @default.
• W2004467890 hasConcept C159654299 @default.
• W2004467890 hasConcept C16224149 @default.
• W2004467890 hasConcept C203014093 @default.
• W2004467890 hasConcept C2777397205 @default.
• W2004467890 hasConcept C2777736543 @default.
• W2004467890 hasConcept C2778506911 @default.
• W2004467890 hasConcept C2779723990 @default.
• W2004467890 hasConcept C2909375385 @default.
• W2004467890 hasConcept C542903549 @default.
• W2004467890 hasConcept C71924100 @default.
• W2004467890 hasConceptScore W2004467890C126322002 @default.
• W2004467890 hasConceptScore W2004467890C142724271 @default.
• W2004467890 hasConceptScore W2004467890C159654299 @default.
• W2004467890 hasConceptScore W2004467890C16224149 @default.
• W2004467890 hasConceptScore W2004467890C203014093 @default.
• W2004467890 hasConceptScore W2004467890C2777397205 @default.
• W2004467890 hasConceptScore W2004467890C2777736543 @default.
• W2004467890 hasConceptScore W2004467890C2778506911 @default.
• W2004467890 hasConceptScore W2004467890C2779723990 @default.
• W2004467890 hasConceptScore W2004467890C2909375385 @default.
• W2004467890 hasConceptScore W2004467890C542903549 @default.
• W2004467890 hasConceptScore W2004467890C71924100 @default.
• W2004467890 hasIssue "10" @default.
• W2004467890 hasLocation W20044678901 @default.
• W2004467890 hasLocation W20044678902 @default.
• W2004467890 hasOpenAccess W2004467890 @default.

• next